Diastolic dysfunction laboratory findings: Difference between revisions
Created page with "__NOTOC__ {{Diastolic dysfunction}} {{CMG}} ==Overview== ==Laboratory Findings== ==References== {{reflist|2}} {{WH}} {{WS}} Category:Cardiovascular diseases [[Category:C..." |
No edit summary |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
Plasma brain natriuretic peptide (BNP) or N-terminal pro b-type natriuretic peptide (NT-proBNP) can be used to diagnose heart failure when diagnosis is unclear. The markers have been found to have lower levels in diastolic dysfunction when compared with systolic dysfunction<ref name="pmid12798574">{{cite journal| author=Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P et al.| title=Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. | journal=J Am Coll Cardiol | year= 2003 | volume= 41 | issue= 11 | pages= 2010-7 | pmid=12798574 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12798574 }} </ref>. Suggested partition values for diagnosis of DHF are BNP >100 pg/mL or NT-proBNP >300 pg/mL. In addition, BNP >100 pg/mL and NT-proBNP >300 pg/mL are independent predictors of adverse cardiovascular events in patients with heart failure with preserved left ventricular ejection fraction<ref name="pmid18773998">{{cite journal| author=Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K et al.| title=Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. | journal=Am J Cardiol | year= 2008 | volume= 102 | issue= 6 | pages= 733-7 | pmid=18773998 | doi=10.1016/j.amjcard.2008.04.048 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18773998 }} </ref>. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 03:58, 21 October 2012
|
Diastolic dysfunction Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Diastolic dysfunction laboratory findings On the Web |
|
American Roentgen Ray Society Images of Diastolic dysfunction laboratory findings |
|
Risk calculators and risk factors for Diastolic dysfunction laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Laboratory Findings
Plasma brain natriuretic peptide (BNP) or N-terminal pro b-type natriuretic peptide (NT-proBNP) can be used to diagnose heart failure when diagnosis is unclear. The markers have been found to have lower levels in diastolic dysfunction when compared with systolic dysfunction[1]. Suggested partition values for diagnosis of DHF are BNP >100 pg/mL or NT-proBNP >300 pg/mL. In addition, BNP >100 pg/mL and NT-proBNP >300 pg/mL are independent predictors of adverse cardiovascular events in patients with heart failure with preserved left ventricular ejection fraction[2].
References
- ↑ Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P; et al. (2003). "Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study". J Am Coll Cardiol. 41 (11): 2010–7. PMID 12798574.
- ↑ Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K; et al. (2008). "Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction". Am J Cardiol. 102 (6): 733–7. doi:10.1016/j.amjcard.2008.04.048. PMID 18773998.